Business
2026 ASCO Preview | Alphamab Oncology to Present Clinical Data of TROP2/HER3 Bispecific ADC JSKN016 for HER2-Negative Breast Cancer
Alphamab Oncology (stock code: 9966.HK) today announced that the results from a Phase I clinical study (JSKN016-101, NCT06592417) of its first-in-class TROP2/HER3 bispecific antibody-drug conjugate (ADC) JSKN016, for the treatment of HER2-negative locally advanced or metastatic breast cancer (BC), will be presented as a poster at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The 2026 ASCO Annual Meeting will be held from May 29, 2026 to June 2, 2026 (local time) in Chicag
About this update from Alphamab Oncology
[{"type":"text","content":"SUZHOU, China, April 23, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) today announced that the results from a Phase I clinical study (JSKN016-101, NCT06592417) of its first-in-class TROP2/HER3 bispecific antibody-drug conjugate (ADC) JSKN016, for the treatment of HER2-negative locally advanced or metastatic breast cancer (BC), will be presented as a poster at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The 2026 ASCO Annual Meeting will be held from May 29, 2026 to June 2, 2026 (local time) in Chicago, the United States.","length":567,"tagName":"p"},{"type":"text","content":"JSKN016-101 (NCT06592417) is a dose-escalation and dose-expansion clinical study in China, enrolling patients with advanced solid tumors to receive JSKN016 monotherapy. The 2026 ASCO Annual Meeting will feature the presentation of analytical results from the HER2-negative BC cohort of this study. JSKN016 demonstrated very promising efficacy and superior safety profile in late line BC patients. The results guarantee the further development of JSKN016, in combo with chemo, IO and target therapy, in front line and perioperative settings.","length":540,"tagName":"p"},{"type":"text","content":"Title: JSKN016, a First-in-Class Anti-TROP2/HER3 Bispecific Antibody-Drug Conjugate (ADC) in Patients (pts) with HER2-Negative Locally Advanced or Metastatic Breast Cancer: Results from a Phase I StudyAbstract Number: 1123Presentation Type: PosterPrincipal Investigator: Professor Herui Yao, Sun Yat-sen Memorial Hospital, Sun Yat-sen UniversityPresentation Time: June 1, 2026, 1:30-4:30 PM CDT","length":398,"tagName":"p"},{"type":"text","content":"JSKN016 is a TROP2/HER3 targeting bispecific ADC developed using the proprietary single-domain antibody and bispecific antibody platforms. It is conjugated via site-specific glycosylation to generate a homogeneous and stable ADC with a drug-to-antibody ratio (DAR) of 4. JSKN016 precisely binds to TROP2 and/or HER3 on tumor cells, blocks tumor signaling pathways, and releases topoisomerase I inhibitors for precise and potent antitumor activity. The glycan conjugation technology confers high stability and low off-target toxicity. Clinical studies have demonstrated encouraging antitumor activity and a favorable safety profile of JSKN016 in heavily pretreated advanced triple-negative breast cance...